BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
The information in this Current Report on Form 8-K (this Current
Report) is being furnished to Item 2.02 of Form 8-K and,
according to general instruction B.2. thereunder, the information
in this Current Report shall not be deemed filed for the purposes
of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that section. The
information in this Current Report shall not be incorporated by
reference into any registration statement to the Securities Act
of 1933, as amended.
On May 11, 2017, Bio-Path Holdings, Inc. (the Company) announced
financial results for the quarter ended March 31, 2017.
Additional information is included in the Companys press release.
A copy of the Companys press release is attached hereto as
Exhibit 99.1. The foregoing description of the press release is
qualified in its entirety by reference to the attached exhibit.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits.
| Exhibit | ||
| Number | Description | |
| 99.1 | Press Release dated May 11, 2017 |
About BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH)
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer. BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Recent Trading Information
BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) closed its last trading session up +0.005 at 0.590 with 144,300 shares trading hands.
